Measuring and improving adherence to osteoporosis pharmacotherapy.
about
Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study.Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data.An Introduction to Health Care Administrative Data.Associations between the 2007 Medicare reimbursement reduction for bone mineral density testing and osteoporosis drug therapy patterns of female Medicare beneficiaries.Accounting for unobservable exposure time bias when using Medicare prescription drug data.The impact of pharmacist interventions on osteoporosis management: a systematic review.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsBisphosphonate prescribing, persistence and cumulative exposure in Ontario, CanadaAdherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.Impact of hospitalization on medication adherence estimation in claims data.Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes.Validity of the days supply field in pharmacy administrative claims data for the identification of blister packaging of medications.Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy.Patient perceptions of the path to osteoporosis care following a fragility fracture.Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence.Variation in the days supply field for osteoporosis medications in Ontario.Advancing the Science and Practice of Medication Adherence.Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?Understanding patient compliance and persistence with osteoporosis therapy.(-)-Epigallocathechin-3-gallate, an AMPK activator, decreases ovariectomy-induced bone loss by suppression of bone resorption.
P2860
Q30841438-12B2AF04-D1E2-496E-A922-707AC431A1BDQ30863128-D27FF94D-1E95-4AF9-8DC9-BB7FD364BD5CQ30979379-0C191001-97E9-4B43-AA5E-974A47A674D6Q33831291-C2DF1FB8-ADB7-4782-ADA6-578DAA4D7903Q35169774-FB69F70B-977A-431F-A3E5-1218074EEEE7Q35204774-6A26FFF8-8953-4BF1-B363-E9649EAB63B2Q35693057-3253E3AB-2604-455F-9040-2DBAEBA0C9D5Q35751437-01234CBA-528D-44EE-9649-211FD2AEB2A9Q35751984-A843E3DF-6405-4DD4-A4B7-1E0745FCB749Q36332518-010D81D1-1216-4F72-88BF-92E609EFE882Q38159780-AD0D712F-F341-45D1-B856-B40B0C5F2376Q38600875-0838464D-F280-4587-BDFC-C4651858BD4CQ38731473-200B7196-69C6-413E-9595-E58D29E53158Q40059033-01ADD50F-5185-49B3-A0B2-05E3E1F09C37Q43678564-6E7CE783-807F-4AF0-A569-8317DA5FDA60Q45364591-DACA6EFB-FBF8-447A-A1CA-4C6BA7083AECQ47567525-DD861773-048D-446D-B41D-5FDCA7463333Q48156007-BE312375-32FC-4477-96F5-DBF6461758A3Q50629816-1C61DFCF-D469-442A-85B5-F43230A9677AQ51351954-BBBFEC1B-8FB7-4D30-83DF-D358B5EE704E
P2860
Measuring and improving adherence to osteoporosis pharmacotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Measuring and improving adherence to osteoporosis pharmacotherapy.
@ast
Measuring and improving adherence to osteoporosis pharmacotherapy.
@en
type
label
Measuring and improving adherence to osteoporosis pharmacotherapy.
@ast
Measuring and improving adherence to osteoporosis pharmacotherapy.
@en
prefLabel
Measuring and improving adherence to osteoporosis pharmacotherapy.
@ast
Measuring and improving adherence to osteoporosis pharmacotherapy.
@en
P2860
P1476
Measuring and improving adherence to osteoporosis pharmacotherapy.
@en
P2093
Andrea M Burden
Suzanne M Cadarette
P2860
P304
P356
10.1097/BOR.0B013E32833AC7FE
P577
2010-07-01T00:00:00Z